Indivior PLC (INDV)

RICHMOND, Va. , Nov. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the ma...

RICHMOND, Va. , Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th Annual Healthcare Conference – New York City, NY Joe Ciaffon...

Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with lower rates of infectious disease complications and im...

Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOY Announces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE® Expect Annual Operating Expense Savings o...

RICHMOND, Va. , Oct. 28, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference: Stifel 2025 Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, ...

RICHMOND, Va. , Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m....

Rapid induction with SUBLOCADE® showed higher treatment retention rates compared to standard induction, particularly among fentanyl-positive participants RICHMOND, Va. , Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published co...

RICHMOND, Va. , Oct. 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it intends to pursue a change in domicile from the U.K. to the U.S. and will establish a new U.S. parent company, Indivior...